Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Capital Expenditures (2018 - 2025)

Historic Capital Expenditures for Arcturus Therapeutics Holdings (ARCT) over the last 8 years, with Q3 2025 value amounting to $181000.0.

  • Arcturus Therapeutics Holdings' Capital Expenditures rose 12625.0% to $181000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $318000.0, marking a year-over-year decrease of 7912.02%. This contributed to the annual value of $648000.0 for FY2024, which is 7766.29% down from last year.
  • Arcturus Therapeutics Holdings' Capital Expenditures amounted to $181000.0 in Q3 2025, which was up 12625.0% from $137000.0 recorded in Q1 2025.
  • Arcturus Therapeutics Holdings' 5-year Capital Expenditures high stood at $3.8 million for Q4 2022, and its period low was $23000.0 during Q2 2022.
  • For the 5-year period, Arcturus Therapeutics Holdings' Capital Expenditures averaged around $882294.1, with its median value being $354000.0 (2023).
  • Its Capital Expenditures has fluctuated over the past 5 years, first tumbled by 9190.14% in 2022, then skyrocketed by 143913.04% in 2023.
  • Arcturus Therapeutics Holdings' Capital Expenditures (Quarter) stood at $1.1 million in 2021, then soared by 240.52% to $3.8 million in 2022, then plummeted by 77.02% to $875000.0 in 2023, then tumbled by 90.86% to $80000.0 in 2024, then skyrocketed by 126.25% to $181000.0 in 2025.
  • Its last three reported values are $181000.0 in Q3 2025, $137000.0 for Q1 2025, and $80000.0 during Q3 2024.